- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SCAN Special Report
European companies try to maintain dominance of global contrastmarketPrice erosion and generic competition top list of concernsProvided they steer a steady course, Schering, Nycomed, and Bracco-- the three European companies that dominate
European companies try to maintain dominance of global contrastmarket
Price erosion and generic competition top list of concerns
Provided they steer a steady course, Schering, Nycomed, and Bracco-- the three European companies that dominate the contrast mediaindustry -- can look forward to slow but steady growth throughthe end of the century. Rising volumes in x-ray contrast agentusage should just about make up for lower prices. The ultrasoundand MRI sectors, yet to take off in the way some industry observershad predicted, should start to pick up as new agents move fromthe R&D laboratory to the market.
But there are pitfalls ahead. Debstabilization awaits the x-raymarket, due to excessive discounting of products that are notnotably different from their competitors, and the threat of competitionfrom generic nonionic agents is on the horizon. In addition, consolidationcould again change the rules of the market if one or more of themain diagnostic imaging players falls victim to the wave of restructuringsweeping over the wider pharmaceutical industry.
Marketline International, a London-based market research company,put the value of the global contrast media market in 1995 at $3.4billion, up 6.5% from the previous year. Since 1993, Japan hasovertaken the U.S. as the largest individual market, worth $1.5billion, or 42.3% of the total.
The value of the European market for nonionic x-ray contrast mediais $600 million, while the value of the MRI contrast market inEurope is $70 million to $80 million, according to Hafslund Nycomedof Oslo, Norway.
The European market is dominated by Nycomed, Schering of Berlin,and Milan-based Bracco, the family-run company in which anotherGerman firm, E. Merck, has a 50% stake. Guerbet of France andMallinckrodt Medical of the U.S. are the final members of theprevailing oligopoly. Schering and Nycomed also dominate the worldmarket. Schering's own figures give it 31% of the world market,and Nycomed 18%, in 1994. Daiichi's 14% share is entirely dueto Japanese sales of the Nycomed product Omnipaque.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
